Advancements in Targeted Therapies for HR+/HER2-Negative Metastatic Breast Cancer: Exploring AKT, PI3K, and Or...
1.0 Credit / Oncology, Breast Cancer, Women’s Health
View More
Strategies for Addressing Cardiovascular Disease, Diabetes, and Chronic Kidney Disease With SGLT2 Inhibitors
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Pharmacist Services to Populations at Risk for HIV: Improving Access and Uptake of Preexposure Prophylaxis
1.0 Credit / HIV/AIDS
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
Eyeing Up OTC Products for Allergic Conjunctivitis: The Pharmacist’s Role in Personalizing Treatment Selection
1.0 Credit / Allergy, Ophthalmology/Optometry, OTC
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
OPC 2025: Early and Metastatic GI Cancers See Practice Changing Trial Results
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.
OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation
June 19th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Mya Tran, PharmD, BCOP, highlights the clinical promise, operational challenges, and evolving role of pharmacists in implementing precision medicine and genomics-driven cancer care.
Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025
June 18th 2025In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.